To counteract this, it has been shown that AT2 receptor gene expression is increased following stroke, but AT2 receptor protein expression remains unchanged in the middle cerebral arteries, which limits the beneficial impact that AT2 receptor agonists may have [84]. The gene discussed is AGTR2; the disease is Stroke.